Treatment of cardiac iron overload in thalassemia major

Haematologica

Volumn 88, Issue 5, 2003, Pages 481-482

  Westwood, Mark ^a   Anderson, Lisa J ^a   Pennell, Dudley J ^a  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHELATING AGENT; DEFERIPRONE; DEFEROXAMINE MESYLATE;

CHELATION; COHORT ANALYSIS; HEART MUSCLE METABOLISM; HUMAN; IRON METABOLISM; IRON OVERLOAD; NOTE; REPRODUCIBILITY; THALASSEMIA MAJOR;

BETA-THALASSEMIA; CARDIOMYOPATHIES; DEFEROXAMINE; DRUG THERAPY, COMBINATION; HEART DISEASES; HUMANS; IRON; IRON CHELATING AGENTS; IRON OVERLOAD; LIVER; MYOCARDIUM; PYRIDONES;

EID: 0038439566     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (17)

1. Modell B, Khan M, Darlison M. Survival in beta thalassaemia major in the UK: data from the UK thalassaemia register. Lancet 2000;355:2051-2.
2. Olivieri NF, Nathan DG, MacMillan JH, Wayne AS, Liu PP, McGee A, et al. Survival in medically treated patients with homozygous β-thalassemia. N Engl J Med 1994;331:574-8.
3. Borgna-Pignatti C, Rugolotto S, De Stefano P, Piga A, Di Gregorio F, Gamberini MR, et al. Survival and disease complications in thalassemia major. Ann N Y Acad Sci 1998;850: 227-31.
4. Weatherall DJ, Pippard MJ, Callender ST. Iron loading in thalassaemia. Five years with the pump. N Engl J Med 1983; 308:456.
5. Anderson L, Bunce N, Davis B, Charrier C, Porter J, Firmin D, et al. Reversal of siderotic cardiomyopathy: a prospective study with cardiac magnetic resonance (CMR). Heart 2001; 85 Suppl 1:33.
6. Freeman AP, Giles RW, Berdoukas VA, Walsh WF, Choy D, Murray PC. Early left ventricular dysfunction and chelation therapy in thalassaemia major. Ann Intern Med 1983;99: 450.
7. Brittenham GM, Cohen AR, McLaren CE, Martin MB, Griffith PM, Nienhuis AW, et al. Hepatic iron stores and plasma ferritin concentration in patients with sickle cell anaemia and thalassaemia major. Am J Hematol 1993;42:81-5.
8. Chapman RW, Hussain MA, Gorman A, Lauricht M, Politis D, Flynn DM, et al. Effect of ascorbic acid deficiency on serum ferritin concentration in patients with beta thalassaemia major and iron overload. J Clin Pathol 1982;35:487-91.
9. Anderson LJ, Holden S, Davis B, Prescott E, Charrier CC, Bunce NH, et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 2001;22:2171-9.
10. Lesnefsky EJ, Allen KG, Carrea FP, Horwitz LD. Iron-catalyzed reactions cause lipid peroxidation in the intact heart. J Mol Cell Cardiol 1992;24:1031-8.
11. Brittenham GM, Griffith PM, Nienhuis AW, McLaren CE, Young NS, Tucker EE, et al. Efficacy of desferrioxamine in preventing complication of iron overload in patients with thalassaemia major. N Engl J Med 1994;331:567.
12. Olivieri NF, Brittenham GM, McLaren CE, Templeton DM, Cameron RG, McClelland RA, et al. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. N Engl J Med 1998;339:417-23.
13. Westwood MA, Anderson LJ, Firmin DN, Gatehouse PD, Charrier CC, Wonke B, et al. A single breath-hold multiecho T2* magnetic resonance technique for diagnosis of myocardial iron overload. J Magn Reson Imaging 2003;17 (in press).
14. Anderson U, Wonke B, Prescott E, Holden S, Walker JM, Pennell DJ. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron levels and ventricular function in β thalassemia. Lancet 2002;360:516-20.
15. Piga A, Gaglioti C, Fogliacco E,Tricta F. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Haematologica 2003;88:489-96.
16. Shalev O, Hileti D, Nortey P, Hebbel RP, Hoffbrand VA. Transport of 14C-deferiprone in normal, thalassaemic and sickle red blood cells. Br J Haematol 1999;105:1081-3.
17. Angelucci E, Muretto P, Nicolucci A, Baronciani D, Erer B, Gaziev D, et al. Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation. Blood 2002;100:17-21.